Premium
Preventive Effects of Lansoprazole and Famotidine on Gastric Mucosal Injury Induced by Low‐Dose Aspirin in Helicobacter pylori —Negative Healthy Volunteers
Author(s) -
Nishino Masafumi,
Sugimoto Mitsushige,
Kodaira Chise,
Yamade Mihoko,
Uotani Takahiro,
Shirai Naohito,
Ikuma Mutsuhiro,
Tanaka Tatsuo,
Sugimura Haruhiko,
Hishida Akira,
Furuta Takahisa
Publication year - 2011
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270010376194
Subject(s) - famotidine , lansoprazole , aspirin , medicine , helicobacter pylori , omeprazole , regimen , gastroenterology , cyp2c19 , crossover study , proton pump inhibitor , pharmacology , placebo , alternative medicine , cytochrome p450 , pathology , metabolism
The preventive effects of lansoprazole and famotidine on low‐dose aspirin‐induced gastric mucosal injury in relation to gastric acidity were compared in healthy Japanese volunteers. Fifteen Helicobacter pylori‐negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion. Gastroscopy for the evaluation of mucosal injury based on modified Lanza score (MLS) and 24‐hour intragastric pH monitoring were performed on day 7 of each regimen. Aspirin induced gastric mucosal injury (median MLS = 3). Lansoprazole significantly decreased MLS to 0, which was significantly lower than that by famotidine (MLS = 1) (P < .05). Medians of pH 3 holding time and mean 24‐hour pH values with the lansoprazole regimen were significantly higher than those with famotidine (P < .05). No significant differences in MLS were observed among the different CYP2C19 genotype groups in any of the treatment regimens. In this 7‐day study, lansoprazole appeared to be more protective than famotidine against low‐dose aspirin‐induced mucosal injury but a larger well‐controlled study is necessary to establish a definitive clinical benefit.